Four hour creatinine clearance is better than plasma creatinine for monitoring renal function in critically ill patients by unknown
Four hour creatinine clearance is better than
plasma creatinine for monitoring renal function
in critically ill patients
Pickering et al.
Pickering et al. Critical Care 2012, 16:R107
http://ccforum.com/content/16/3/R107 (19 June 2012)
RESEARCH Open Access
Four hour creatinine clearance is better than
plasma creatinine for monitoring renal function
in critically ill patients
John W Pickering1*, Christopher M Frampton1, Robert J Walker2, Geoffrey M Shaw1,3 and Zoltán H Endre1,4
Abstract
Introduction: Acute kidney injury (AKI) diagnosis is based on an increase in plasma creatinine, which is a slowly
changing surrogate of decreased glomerular filtration rate. We investigated whether serial creatinine clearance, a
direct measure of the glomerular filtration rate, provided more timely and accurate information on renal function
than serial plasma creatinine in critically ill patients.
Methods: Serial plasma creatinine and 4-hour creatinine clearance were measured 12-hourly for 24 hours and then
daily in 484 patients. AKI was defined either as > 50% increase in plasma creatinine from baseline, or > 33.3%
decrease in creatinine clearance. The diagnostic and predictive performance of the two AKI definitions were
compared.
Results: Creatinine clearance decrease diagnosed AKI in 24% of those not diagnosed by plasma creatinine increase
on entry. These patients entered the ICU sooner after insult than those diagnosed with AKI by plasma creatinine
elevation (P = 0.0041). Mortality and dialysis requirement increased with the change in creatinine clearance-acute
kidney injury severity class (P = 0.0021). Amongst patients with plasma creatinine < 1.24 mg/dl on entry, creatinine
clearance improved the prediction of AKI considerably (Net Reclassification Improvement 83%, Integrated
Discrimination Improvement 0.29). On-entry, creatinine clearance associated with AKI severity and duration (P <
0.0001) predicted dialysis need (area under the curve: 0.75) and death (0.61). A > 33.3% decrease in creatinine
clearance over the first 12 hours was associated with a 2.0-fold increased relative risk of dialysis or death.
Conclusions: Repeated 4-hour creatinine clearance measurements in critically ill patients allow earlier detection of
AKI, as well as progression and recovery compared to plasma creatinine.
Trial Registration: Australian New Zealand Clinical Trials Registry ACTRN012606000032550.
Introduction
Acute kidney injury (AKI) is common in critically ill
patients and is frequently fatal [1-5]. Although defined
as an abrupt decrease in glomerular filtration rate (GFR)
[6,7] there are no real time measures of GFR to enable
timely diagnosis. In practice, diagnosis depends on
observing an increase in plasma creatinine (pCr);
according to creatinine kinetics, this may not become
apparent until 24 to 72 hours after a decrease in GFR
[8]. This temporal disconnect between changed GFR
and pCr is readily observable, particularly where there is
a clearly defined time of injury, such as cardiopulmonary
bypass surgery. The relationship is less clearly demon-
strated following multiple or continuing injury and after
vigorous resuscitation. The relationship between change
in GFR and change in plasma creatinine has not been
investigated in critically ill patients at high risk of AKI.
In contrast, numerous urinary and plasma biomarkers of
kidney injury are under investigation, and are usually
assessed by their ability to predict an increase in creati-
nine [9,10]. Although, many biomarkers show promise
as predictors of change in renal function, of dialysis
need and of mortality, their primary biological role is to
mark the presence of renal injury. With the exception of
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plasma cystatin C, these biomarkers are not markers of
function.
Creatinine clearance (CCl) is an easy to estimate GFR
in the intensive care unit, since most patients are cathe-
terised and have frequent measurements of pCr. In
patients with normal creatinine a low CCl may be an
early indicator of AKI [11]. Several studies have shown
that short duration (1 to 4 h) CCl measures are feasible
in the critically ill [11-14]. Several of these evaluated
CCl by comparing short duration clearance with 24-h
clearance [12-14]. While validating the brief clearance
technique, these studies did not evaluate the use of brief
CCl in the detection of AKI.
Evaluation of 4-h CCl was a planned component of
the two-centre Early intervention in Acute Renal Failure
(EARLYARF) randomised controlled trial of high dose
erythropoietin for the prevention of AKI in the ICU
[15]. We hypothesised that CCl would give more timely
and accurate information on renal function than pCr.
We compared these metrics in the diagnosis of AKI and
AKI severity and as predictors of the need for dialysis
and mortality. We also compared these metrics with
urine output. Finally, we compared serial measurements
of CCl with serial measurements of pCr.
Materials and methods
The study was approved by the multiregional ethics
committee of New Zealand (MEC/050020029) and regis-
tered under the Australian New Zealand Clinical Trials
Registry (ACTRN012606000032550 [16]). Screening on
entry to the ICU was by presumptive consent, followed
by written consent from the patient or family.
Inclusion and exclusion criteria, consent procedures,
estimation of time after renal injury, and creatinine
assays have been described in detail elsewhere [15].
Briefly, patients were excluded if they were not
expected to remain in the ICU for 24 h or to survive
72 h; anuric; receiving renal replacement therapy, or
had obvious haematuria, rhabdomyolysis or polycythe-
mia. There was no significant difference between
means or standard deviations of creatinine reference
samples between the laboratories at the two centres.
Since erythropoietin had no effect on outcome in the
EARLYARF trial, this analysis includes patients in
both observation and intervention arms [15]. Plasma
and urine samples were taken for assay and a 4-h
urine collection commenced on entry to ICU at 12
and 24 h post-entry and then daily for 7 days. CCl
was calculated in ml/min (Table 1). Baseline renal
function in patients with known baseline creatinine
was determined by the Cockcroft-Gault (CG) equation
[17]. The average urine output per kg of body-weight
(UO in ml/kg/hr) was measured on entry to the ICU
(Table 1).
Cohorts with known and unknown baseline creatinine
The cohort was divided into those with a known baseline
creatinine (n = 182) and those without (n = 302). Known
baseline creatinine was defined as a measured value
within one year of entry to the ICU (n = 162), or for elec-
tive surgery patients, the pre-surgery sample (n = 20).
Definitions of AKI
The known baseline creatinine cohort was used to test
the hypothesis that the estimated change in CCl was a
better predictor of outcomes than the change in creati-
nine (ΔpCr). AKI was defined by an increase in pCr
(ΔpCrAKI), or an estimated decrease in CCl (ΔCClAKI),
Table 1 Definitions
Name Abbreviation Calculation
Creatinine Clearance CCl (Urine creatinine concentration/Plasma creatinine concentration) × (Volume of urine collected over 4
hours in ml/(4 × 60))
Cockcroft-Gault clearance
[17]
CG [(140-Age in years) × weight in kg/(72 × Plasma creatinine concentration in mg/dl)] × 0.85 if female
Average urine output UO Volume of urine collected over 4 hours in ml/(4 × Patient weight in kg)
Change in CCl ΔCCl 100 × (Measured CG on entry - baseline CCl)/Baseline CG
Change in plasma
creatinine
ΔpCr 100 × (On entry creatinine - baseline creatinine)/Baseline creatinine
AKI plasma creatinine ΔpCrAKI ΔpCr > 50%
AKI creatinine clearance ΔCClAKI ΔCCl < -33.3%
AKI urine output
(oliguria)
UOAKI Urine output < 0.5 ml/kg/hr on average over 4 hours
RIFLE class R R ΔpCr > 50% and ≤ 100%, or ΔCCl < -33.3% and ≥ -50%
RIFLE class I I ΔpCr > 100% and ≤ 200%, or ΔCCl < -50% and ≥ -66.7%
RIFLE class F F ΔpCr > 200% or ΔCCl < -66.7%
AKI from entry (AKIN) AKIAKIN (Plasma creatinine - on entry plasma creatinine) > 0.3 mg/dl or 50% within 48 hours
AKI: acute kidney injury; RIFLE: Risk, Injury, Failure, Loss, End stage.
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or as oliguria (UOAKI). Each component approximates a
diagnostic criterion of the Risk, Injury, Failure, Loss,
End stage (RIFLE) definition [6,18]. Because urine out-
put was measured over 4 h only, oliguria was only
defined over this duration rather than the 6-h RIFLE
period. Patients were further classified into (i) no AKI
(ΔpCrNo-AKI and ΔCClNo-AKI); (ii) AKI by the clearance
criterion only (ΔpCrNo-AKI and ΔCClAKI); (iii) AKI by
the pCr criterion only (ΔpCrAKI and ΔCClNo-AKI) or (iv)
AKI by both criteria (ΔpCrAKI and ΔCClAKI). Finally,
patients were classified according to AKI RIFLE severity
class (Table 1).
CCl and pCr cut-points and risk prediction models
The area under the receiver operator characteristic
curve (AUC) was used to determine the predictive value
of on-entry CCl for ΔCClAKI and on-entry pCr for
ΔpCrAKI. For each metric the optimal cut-point was
determined as the value nearest to a sensitivity and spe-
cificity of one. We were most interested in whether the
addition of CCl to existing measurements of pCr and
UO helps identify patients with AKI when pCr is low.
Therefore, in the cohort with pCr less than the optimal
cut-point, a reference risk prediction model (logistic
regression) for AKI (either ΔCClAKI or ΔpCrAKI) was
constructed using pCr, UO and other variables asso-
ciated with AKI on univariate analysis. The model calcu-
lates for each patient the probability of having AKI. To
assess the added benefit of CCl, a new model was con-
structed by adding CCl to the reference model and was
compared with the reference model.
Using the entire cohort, the on-entry creatinine and
on entry CCl and pCr were compared as predictors of
AKI and severity stage according to the AKIN (Acute
Kidney Injury Network) criteria [7] (AKIAKIN), duration
of AKIAKIN, death within 30 days and 365 days, need for
dialysis, and length of ICU stay.
Statistical analysis
Results are presented as means ± SD or medians and
inter-quartile range (IQR), or incidence presented as
number (n). Cohorts were compared with the Student’s
t-test (for normally distributed continuous variables),
the Mann-Whitney U-test (for variables not normally
distributed), and the chi square (c2) or Fisher’s exact
test for categorical variables. Length of ICU stay was log
transformed as necessary for assessment of association
with AKI severity class, using one-way analysis of var-
iance (ANOVA). Diagnostic and prognostic performance
was assessed by calculating the AUC and odds ratios.
The reference and new AKI risk prediction models were
compared by the continuous (category-free) net reclassi-
fication improvement (NRI) and integrated discrimina-
tion improvement statistics [19-21] and difference in
AUC [22]. GraphPad Prism 5.0a for Mac OS (GraphPad
Software, San Diego, CA, USA) and Matlab 2011a
(MathWorks, Natick, MA, USA) were used for statistical
analyses. All confidence intervals (CIs) are 95%.
Results
Of the 528 patients enrolled in the EARLYARF trial, 484
had a CCl measure on entry to the ICU. Of the remain-
der, 30 were a sub-cohort of high-risk patients who had
undergone cardio-thoracic surgery, and whose first
clearance measure was 8 to 11 h after entry to ICU, and
14 patients had no clearance measurement because they
were anuric or because clinical events prevented mea-
surement. The analysis is based on 484 patients. Patient
characteristics are shown in Table 2.
AKI on entry to ICU (known baseline creatinine cohort)
On entry to the ICU, 182 patients had a pre-admission
baseline creatinine from which the change in creatinine
(ΔpCr) and change in creatinine clearance (ΔCCl) to
Table 2 Patient demographics (n = 484) on entry to the
ICU
Age, yrs 60 ± 17
Female, % (n) 39 (190)
Weight, kg 79 ± 19
Baseline pCr, mg/dl 0.86 (0.71, 1.06)
Baseline estimated CCl, ml/min 89 (66, 125)
APACHE II score 18 ± 6
SOFA score 6.3 ± 2.8
Hypotension, % (n) 23 (111)
pCr, mg/dl 1.0 (79.0, 1.36)
4-h CCl, ml/min 78 (48, 122)
Urine output, ml/kg/hr 1.0 (52, 2.14)
Urine creatinine, mg/dl 62 (30, 107)
Plasma cystatin C, mg/dl 86 (66, 1.2)
CKD, % (n) 14 (66)
Primary diagnosis, % (n)
Abdominal aortic aneurysm rupture & repair 5 (22)
Abdominal surgery or inflammation 11 (51)
Burns 1 (5)
Cardiac arrest or failure 13 (63)
Cardiac surgery 13 (64)
Collapse, cause unknown 1 (3)
Neurological surgery, injury or seizure or haemorrhage 15 (71)
Other 1 (3)
Pulmonary or thoracic surgery or failure 13 (63)
Sepsis 20 (97)
Traumaa 9 (42)
Shown are means ± SD or medians (lower quartile, upper quartile) for normal
and non- normally distributed data, or percentage (n).
pCr: plasma creatinine; CCl: creatinine clearance; CKD: chronic kidney disease;
APACHE: acute physiology and chronic health evaluation SOFA: Sequential
Organ Failure Assessment.
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determine AKI status on entry was calculated (Figure 1).
The ΔpCr only poorly approximated that expected from
ΔCCl (r2 = 0.18) according to the creatinine kinetic
model [23]:
pCr = 100*[1/(1 + CCl/100) - 1]
Ninety-two patients (51%) had AKI according to
ΔCClAKI, ΔpCrAKI or UOAKI. Thirty-seven percent (n =
14) of ΔpCrAKI were not simultaneously ΔCClAKI,
whereas 24% (n = 34) of ΔpCrNo-AKI had AKI according
to ΔCClAKI (Table 3). Twenty more patients were classi-
fied as AKI by ΔCClAKI than by ΔpCrAKI (McNemar’s
test P < 0.01). Although 14 more patients were classified
as UOAKI than ΔpCrAKI, and a 6 more by ΔCClAKI than
UOAKI, the differences were not significant (P = 0.07
and P = 0.49 respectively). Sixteen patients had AKI by
all three definitions. Ten of these sixteen patients died
or needed dialysis within 30 days (relative risk (RR) 4.1
compared with not meeting all three definitions; 95%
CI, 2.7 to 6.4). ΔCClAKI severity classifications were


























Figure 1 Comparison of percentage increase in plasma creatinine (pCr) with percentage decrease in creatinine clearance (CCl) from
known baseline to entry into the ICU. Four quadrants are shown: (i) No AKI (ΔpCrNo-AKI and ΔCClNo-AKI), (ii) AKI by the clearance criterion only
(ΔpCrNo-AKI and ΔCClAKI), (iii) AKI by the pCr criterion only (ΔpCrAKI and ΔCClNo-AKI) or (iv) AKI by both criteria (ΔpCrAKI and ΔCClAKI). AKI: acute
kidney injury; No-AKI (CClNo-AKI): without AKI; ΔpCr: relative change in pCr from baseline; ΔCCl: relative change in CCl from Cockcroft-Gault (CG)
baseline; AKI (pCrAKI): with AKI.
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associated with increased 30-day mortality or need for
dialysis (c2 test for trend, P = 0.0021), but not ΔpCrAKI
(P = 0.12) (Figure 2). Length of ICU stay was not asso-
ciated with ΔCClAKI (P = 0.49) or ΔpCrAKI severity clas-
sifications (P = 0.95).
The time from insult until entry to the ICU differed
between groups (P = 0.0041, Kruskal Wallis non-para-
metric ANOVA). Thirty-four patients were ΔCClAKI and
ΔpCrNo-AKI. Their median time from insult until entry
to the ICU, 10.8 h (IQR, 5.0 to 20.0 h), was less than
those classified as ΔpCrAKI and ΔCClAKI, for whom the
equivalent figure was 24.6 h (IQR, 17.0 to 50.0 h) (P =
0.0037; Mann-Whitney U-test) and was less than
ΔpCrAKI and ΔCClNo-AKI, at 18.7 h (IQR, 9.8 to 48.0 h),
but not significantly so (P = 0.079). Four ΔCClAKI and
ΔpCrNo-AKI patients developed AKI according to ΔpCr
at a later time point, and three further patients died
within seven days.
CCl as a risk factor for AKI on entry to ICU when pCr is
low (known baseline creatinine cohort)
The optimal cut-point for CCl to diagnose ΔCClAKI
was 48.6 ml/min (AUC, 0.87; 95% CI, 0.81 to 0.94) cal-
culated using 1/CCl) in the known baseline creatinine
cohort (Figure 3). The optimal cut-point for pCr to
diagnose ΔpCrAKI was 1.24 mg/dl (AUC, 0.91; 95% CI,
0.85 to 0.98). Below this cut-point adding CCl to a risk
prediction model comprising pCr, UO and acute phy-
siology and chronic health evaluation (APACHE) II
scores (all P < 0.1 in a univariate analysis) for AKI
(ΔCClAKI or ΔpCrAKI) considerably improved the
model: in the known baseline creatinine cohort the
AUC increased by 0.23 to a moderate 0.77; a net 23%
of those with AKI had greater risk whilst 60% of those
without AKI had less risk, resulting in an NRI of 83%;
the average increase in risk of those with AKI was 0.22
(IDIAKI) and the average decrease in risk of those with-
out AKI was 0.074 (IDINo-AKI) indicating the model
worked best to improve identification of those with
AKI rather than exclude those without (Table 4). At a
cut-point of CCl = 48.6 ml/min, the positive predictive
value (PPV) was 0.88 and the negative predictive value
(NPV) was 0.65.
Prognosis on entry to ICU (entire cohort)
On-entry CCl, pCr, and UO were associated with maxi-
mum severity of AKI observed over the next 48 h
(AKIAKIN: P < 0.0001, P < 0.0001, P = 0.035 respectively,
Mann-Whitney U- test) (Figure 4). CCl and pCr, but
not UO were also associated with duration of AKIAKIN
(P < 0.0001, P < 0.0001, P = 0.79 respectively).
On entry to the ICU, CCl moderately predicted the
need for dialysis marginally better (AUC, 0.75; 95% CI,
0.59 to 0.91; P = 0.018) than pCr (AUC, 0.72; 95% CI,
0.56 to 0.89); UO was not predictive (AUC, 0.50; 95%
CI, 0.41 to 0.75). CCl was predictive of death within 30
days, but with a lower AUC value of 0.61 (95% CI, 0.54
to 0.68). Neither pCr (AUC, 0.55; 95% CI, 0.48 to 0.62)
nor UO (AUC, 0.55; 95% CI, 0.47 to 0.62) were predic-
tive of death.
Change in CCl after entry to ICU
CCl decreased by > 33.3% over the first 12 hours in 72
patients (14.9%) following ICU entry. These patients
were more likely to require dialysis or die within 30
days than patients with smaller decreases (29% vs 15%,
P = 0.0057; RR, 2.0; 95% CI, 1.3 to 3.0). Only sixteen
patients (22%) had a subsequent increase in pCr of
more than 50% as would be expected by creatinine
kinetic modelling. The median (IQR) time for this
increase from the on-entry sample was 25 (17 to 44) h.
This was greater than the 16 h required to measure the
33.3% decrease in 4-h CCl required to diagnose AKI; P
= 0.0046, Mann Whitney U-test. Of the other 56
patients, 21 had very high on-entry CCl (> 140 ml/min),
two-thirds of whom were admitted following head
injury, neurological surgery, stroke or Guillian Barre
syndrome; 22 had a transient decrease in CCl (resolved
by 24 h) which may explain the lack of increase in pCr;
3 exhibited elevations in pCr of 29 to 47% (that is, less
than the 50% required for AKI classification); 3 patients
did not exhibit any significant changes in pCr and seven
had no subsequent CCl measurements.
Thirty-six patients exhibited a rise in pCr > 50% but
no decrease in CCl over 12 h. Of these, 27 had a
decrease in CCl on entry (23) or by 24 h (4) from the
CG baseline greater than 33.3% (determined retrospec-
tively); 5 had decreases of CCl > 33.3% between later
time points (between day 2 and day 3) followed by an
increase in pCr, and 4 showed no decrease in CCl pre-
ceding a increase in pCr.
Discussion
The measurement of a brief CCl, relative to a known
baseline value (or when unknown, relative to a calcu-
lated CG baseline value), provided earlier diagnostic
and prognostic information, compared with change in
pCr alone. AKI on entry to the ICU was identified in
Table 3 Cross-tabulation of Risk, Injury, Failure, Loss, End
stage (RIFLE) on entry in the known baseline creatinine
cohort according to the definition
ΔCClNo-AKI ΔCClAKI UONo-AKI UOAKI
ΔpCrNo-AKI 110 34 111 33
ΔpCrAKI 14 24 19 19
ΔCClNo-AKI 101 23
ΔCClAKI 29 29
AKI: acute kidney injury; AKI (pCrAKI): with AKI; No-AKI (CClNo-AKI): without AKI;
CCl: creatinine clearance; pCr: plasma creatinine.
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one third of patients not identified by pCr. After
admission to the ICU, these patients were identified
earlier than those identified by ΔpCr, consistent with
the delay in pCr equilibration suggested by creatinine
kinetics. ΔCCl also identified a cohort of patients, the
(ΔpCrAKI and ΔCClNo-AKI) group, with normal renal
clearance but with an increased pCr, consistent with
recovering renal function after an earlier loss of GFR.
This mistiming between CCl measurement and steady
state pCr potentially explains the poor correlation (r2
= 0.18) observed. The probability of death or dialysis
was more closely associated with the ΔCCl RIFLE
severity grade than with ΔpCr severity grade. Serial
measurements of CCl provided a diagnosis of AKI and
of improving renal function earlier than serial mea-
surements of pCr and also identified patients at risk of
dialysis.
A low on-entry CCl was associated with poor out-
come, including death. In contrast, neither UO nor pCr
predicted death. The moderate AUCs indicate that CCl
is not a useful stand-alone predictor of death. When
added to a risk prediction model for AKI in patients
with low on-entry pCr (< 1.24 mg/dl), CCl greatly
improved the model. A sub-threshold CCl predicted the
development of AKI and was associated with severity of
AKI when AKI was determined using the on-entry crea-
tinine as baseline. The combination of a normal pCr (<
1.24 mg/dl) and low CCl (< 48.6 ml/min) had a moder-
ately high predictive value (0.88) for the early detection
of AKI.
Patients with a low CCl and increased pCr need addi-
tional information to distinguish on-entry AKI from
chronic kidney disease (CKD) in the absence of a pre-
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Figure 2 Comparison of plasma creatinine (pCr) change with estimated creatinine clearance (CCl) change acute kidney injury (AKI)
severity classes (No-AKI, R, I or F) on entry to the ICU in the known baseline creatinine cohort. Percentage of patients who died or
needed dialysis; ΔpCr, P = 0.12, ΔCCl, P = 0.0055 (c2 test for trend). The number above each bar is the number of patients who died/total
number.
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Figure 3 Comparison of creatinine clearance (CCl) with plasma creatinine (pCr) on entry into the ICU in the (A) known baseline cohort
and (B) entire cohort. Dashed lines represent optimum cut-points for diagnosis of acute kidney injury (AKI) according to a change in CCl (CCl <
48.6 ml/min) or change in pCr (pCr > 1.24 mg/dl). (A) The four possible diagnoses (i) No AKI (ΔpCrNo-AKI and ΔCClNo-AKI), (ii) AKI by the clearance
criterion only (ΔpCrNo-AKI and ΔCClAKI), (iii) AKI by the pCr criterion only (ΔpCrAKI and ΔCClNo-AKI) or (iv) AKI by both criteria (ΔpCrAKI and ΔCClAKI)
are illustrated by squares for ΔpCrAKI and closed circles or squares for ΔCClAKI. (B) Oliguric (urine output < 0.5 ml/kg/h average over 4 h, closed
circles), and non-oliguric (open circles) for the entire cohort. No-AKI (CClNo-AKI): without AKI; ΔpCr: relative change in pCr from baseline; ΔCCl:
relative change in CCl from Cockcroft-Gault (CG) baseline; AKI (pCrAKI): with AKI.
Pickering et al. Critical Care 2012, 16:R107
http://ccforum.com/content/16/3/R107
Page 7 of 12
of oliguria alone in this group was not sufficient to dis-
tinguish patients with CKD from those with AKI (data
not shown). Underlying CKD causes the relative
increase in pCr to be lower, potentially delaying diagno-
sis of AKI if a relative change in creatinine is used for
diagnosis [24]. An absolute rise in creatinine allows
diagnosis to be independent of the underlying function
[24]. However, for early diagnosis, injury biomarkers not
associated with CKD are needed to identify on-entry
AKI from CKD without AKI. Unfortunately, amongst
the injury markers we measured in this cohort (with
time course of sufficient duration to be increased when
pCr was increased) biomarker performance depended
on baseline renal function [10] which makes interpreta-
tion difficult when the patient has CKD. Only 22% of
patients (n = 16) with an initial one third decrease in
CCl subsequently developed a 50% increase in pCr as
predicted by the creatinine kinetic model. Serial mea-
surements were needed to identify patients with only a
transient decrease in CCl. Some of the false positives in
this group reflected a high initial CCl, suggesting cau-
tion when interpreting a decrease in CCl if the initial
CCl baseline is high (> 140 ml/min).
The optimum frequency for monitoring loss of GFR
remains to be determined, and near real-time measure-
ments of GFR are possible [8]. In this study, CCl was
measured on entry to the ICU and then 12 hourly.
Since urine output is measured hourly in most ICUs,
the frequency of CCl measurements could easily be
increased with more frequent plasma and urine
creatinine sampling. CCl would then have the potential
to provide earlier information on worsening of AKI
severity and to facilitate interpretation of changes in
pCr. For example, while a modest increase in pCr sug-
gests progression of severity, for example, from RIFLE
stage R to stage I, renal function may remain
unchanged. An unchanged CCl would demonstrate that
the apparent progression represented a prior, rather
than a continuing decrease in GFR. Detection of a true
decline in renal function requires demonstration of
incremental loss of GFR, which may be detected by
serial CCl measurements but not initially by serial pCr
measurement. CCl may also be preferable to pCr for
other clinical purposes, such as calculation of dose for
renal-excretion drugs [25], or for triaging patients in
trials in AKI, aiming to intervene after a decrease in
GFR but prior to creatinine increase, so-called secondary
prevention [26].
Alone, the urine output criterion for diagnosis of AKI
was not a reliable alternative to CCl. Consistent with
these findings, Prowle et al. recently demonstrated that
most episodes (94%) of oliguria were not associated with
AKI (RIFLE I by the creatinine- change criterion) the
next day [27]. As discussed, there are many modifiers of
urine output in critically ill patients, including the
administration of fluids and diuretics, and impaired abil-
ity for urinary concentration in some patients with
CKD.
The search for new biomarkers of AKI has aimed to
identify injury that leads to significant loss of GFR, as
Table 4 Risk reclassification using creatinine clearance plus clinical predictors (plasma creatinine, urine output, and
APACHE II) compared with the clinical model alone for AKI on entry.
Known baseline creatinine cohort, pCr ≤ 1.24 mg/dl (n = 111)
Comparison of model performance
IDIAKI 0.22 (0.09 to 0.38)
IDINo-AKI 0.074 (0.029 to 0.13)
IDI 0.29 (0.12 to 0.49)
NRIAKI 23 (-9.2 to 56)
NRINo-AKI 60 (34 to 76)
NRI 83 (29 to 125)
Increase in AUC 0.23 (0.015 to 0.41)
Combined CCl and clinical predictors model performance
AUC 0.77 (0.66 to 0.88)
IS 0.45 (0.29 to 0.61)
IP 0.16 (0.099 to 0.25)
PPV at < 48.6 ml/min 0.88 (0.81 to 0.94)
NPV at < 48.6 ml/min 0.65 (0.46 to 0.85)
Cut-point (ml/min) for PPV > 90% < 78
Cut-point (ml/min) for NPV > 90% < 38.7
Values in brackets represent 95% confidence intervals. APACHE: acute physiology and chronic health evaluation; IDI: integrated discrimination improvement; NRI:
net reclassification improvement (continuous/category free); AUC: Area under the receiver operator characteristic curve (ideally = 1); Increase in AUC: difference in
AUC between the combined model and the clinical predictors only model; CCl: creatinine clearance; IS: integrated sensitivity (ideally = 1); IP: integrated 1-
specificity (ideally = 0); PPV: positive predictive value; NPV: negative predictive value.
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an alternative to waiting for GFR-induced change in
pCr. Nevertheless, most biomarker studies have relied
on change in creatinine, the surrogate for change in
GFR, on the assumption that pCr changes follow a sim-
ple creatinine kinetic model [28]. This was the assump-
tion behind the RIFLE definition of equating a
percentage increase in pCr with a percentage decrease
in GFR [6,18]. Although the AKIN removed change in
GFR from the RIFLE, we have argued that the principal
of measuring a change in GFR should be retained as the
gold standard in the definition of AKI [29]. While await-
ing a commercially available real-time measure of GFR,



































































































































Figure 4 Comparison of on entry plasma creatinine (pCr), urine output (UO), and creatinine clearance (CCl) in the entire cohort with:
(i) AKIAKIN severity classes (No AKI, I, II or III) determined from on entry pCr and CCl and UO, (ii) Duration of AKIAKIN. Post-hoc *** P <
0.001, ** P < 0.01, * P < 0.05.
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we postulate that serial CCl may allow identification of
the specific phase of injury in AKI [26]. Brief CCl could
also help determine whether a particular injury biomar-
ker was increased before or after a decrease in GFR,
which may also facilitate appropriate intervention. In a
recent AKI biomarker study, the difference between the
estimated baseline and 12-h CCl within 48 h of ICU
admission was used to define patients with AKI [30].
This enabled the study to assess the effectiveness of a
combination of pCr and urinary gamma-glutamyltran-
speptidase in AKI detection. This suggests that change
in CCl may be independently useful as a selection criter-
ion for early intervention.
A low CCl (in our study < 48.6 ml/min) on entry to
the ICU indicates that individuals are at high risk of
AKI. We suggest this should lead to the appropriate
management recommended by the Kidney Disease:
Improving Global Outcomes (KDIGO) consortium (see
Figure 4 in [31]). This comprises: discontinuation of
nephrotoxic agents, maintenance of perfusion pressure
and volume status, further haemodynamic monitoring,
continued monitoring of serum creatinine and urine
output, avoidance of hyperglycaemia and contrast proce-
dures, and additional diagnostic workups. In addition,
we recommend further CCl monitoring. As a research
tool, where available, measurement of biomarkers of
kidney injury could assist in establishing the diagnosis of
AKI [32,33]. In contrast, if CCl on entry to the ICU is
normal in the presence of an increased pCr, patients
may be stratified to lower risk. At this stage, we would
recommend at least one more 4-h CCl to confirm nor-
mal clearance. Clearly, biomarkers of acute kidney injury
could be helpful here too, if available. Clearly all patients
who appear to have had a short episode of AKI prior to
entry to ICU should have nephrology follow up after
discharge to check for progression to CKD.
Limitations
There are limitations in the use of a CCl to estimate
GFR. A measured CCl is averaged over the collection
period and requires pre- and post or mid-point pCr
measurement. If the time interval is brief pCr is unlikely
to change substantially. If the interval is too brief, rela-
tive errors in measurement of urine output may be
increased. We suggest that 2 to 4 h is a reasonable and
practical compromise. We recently demonstrated in
these same patients that a 4-h clearance could detect
the early phase decrease in CCl that characterises the
initial phase of patients developing AKI [34]. The costs
associated with CCl, are minimal, simply more frequent
assays of urine and pCr, with careful attention to
recording urine output accurately.
The optimal frequency for CCl measurements is
uncertain. In a patient with oliguria, urine collection for
less than 1 to 2 h will be relatively inaccurate. Assuming
laboratory turnaround was 2 h or less, the maximum
frequency of clearance measurements would be 3- to 4-
hourly, which may set a reasonable minimum interval
over which to review change based on creatinine excre-
tion data. Clearly, given time and cost, these measure-
ments should be undertaken on entry to the ICU to
establish a baseline, but only repeated at this frequency
in patients at high risk of, or already suspected of having
AKI.
Few studies have compared short duration CCl in the
ICU with direct measures of GFR. Robert et al. com-
pared inulin clearance with 30-minute CCl in 20 conse-
cutive ICU patients [35]. Whilst there was no
statistically significant bias, the 95% CI of the difference
was large (-88 to 74 ml/min) although halved by the
removal of two apparent outliers. Wharton et al. com-
pared inulin clearance, 99 mTc-DTPA and 2-h CCl in 18
acute patients with AKI [36]. Again there was no bias.
The 95% CI for the difference was from -33 to +16 ml/
min for inulin and -20 to +11 ml/min for 99 mTc-DTPA.
Hilbrands et al. measured CCl during simultaneous inu-
lin and EDTA clearance (1.5 h) [37]. CCl overestimated
GFR by about 20%, a difference that disappeared follow-
ing cimetidine administration. Hoste et al. compared 1-
h CCl in ICU patients with normal pCr with CG and
modified diet in renal disease (MDRD) estimations of
GFR [11]. The difference between these equations and
CCl was large and clinically significant. They concluded
that these equations were not acceptable alternatives to
measured CCl.
The rapid loss of GFR causes rapid changes in creati-
nine excretion [38]. Initially excretion falls in proportion
to the loss of GFR followed by a gradual increase in
excretion in proportion to the gradual increase in pCr
concentration (see Figure five in [34]). CCl is therefore
influenced initially by the fall in creatinine excretion,
and later by any change in plasma concentration. Errors
will be introduced by factors which independently alter
creatinine excretion. For example, CCl overestimates
GFR because of tubular secretion of creatinine, which
approximates 10 to 20% at normal GFR but increases
with declining GFR [37,39]. While cimetidine inhibition
of tubular creatinine secretion improves GFR estimates
[37,40], this may interfere with other drug excretion and
is probably not useful in the timeframe of AKI. A
change in renal blood flow which induces AKI may also
directly modify creatinine secretion, but there is little
evidence from which to quantify this. CCl is likely to be
unreliable when there is polyuria, such as in diabetes
insipidus or, when acute brain injury is causing cerebral
salt wasting [41].
Finally, as with pCr, change in clearance requires a
baseline value for interpretation. This will be absent in
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many cases. Estimation equations perform poorly when
used to estimate a baseline creatinine [42-44]. Similarly,
it will not always be possible to decide if a measured
CCl on admission to the ICU reflects baseline renal
function or a loss of function. We used the CG formula
to estimate baseline clearance. Whilst other formulas
are more precise estimates of GFR, it was appropriate to
use an estimate of CCl as a baseline for calculation of
change in CCl, potentially minimising some of the error
introduced by creatinine secretion. Using the MDRD
formula made minimal difference (results not shown).
Additional clinical information is also required to sepa-
rate those with CKD from those with AKI on entry to
the ICU.
Conclusions
In a high-risk clinical setting, short duration CCl mea-
surement is useful for patients with a known baseline
creatinine for whom a CG estimation of baseline CCl
can be made or when pCr is low. In this setting, low
CCl suggests an acute loss of renal function and will
influence drug dosing, initiate avoidance of known
nephrotoxins, and trigger early nephrology consultation.
Regular additional CCl would monitor recovery. Further,
larger studies are required to determine the optimum
frequency and duration of CCl measurement.
When pCr is increased in a patient with normal base-
line values, 4-hourly CCl can distinguish resolving and
ongoing renal impairment.
CCl may be useful in clinical trials by identifying
patients soon after loss of renal function and before pCr
is elevated, or by excluding patients when renal function
is impaired.
Key Messages
• Repeated 4-h CCl in the ICU are viable
• Low 4-h CCl in the presence of a normal pCr indi-
cates recent loss of renal function
• Normal 4-h CCl in the presence of an increased
pCr indicates renal recovery
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